|
PHASE I AND II CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS
|
N01CN035158-009
|
$1,500,000
|
$1,500,000
|
CHOW, SHERRY
|
ARIZONA UNIV:1109859
|
|
High Throughput Screens of Novel Radiation Sensitizers and Protectors
|
1R01CA124635-01A2
|
$296,018
|
$148,009
|
Morgan, William
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$38,496
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Molecular Mechanisms by which Rexinoids Prevent Breast Cancer
|
5R01CA078480-11
|
$341,085
|
$341,085
|
BROWN, POWEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
High Content Analysis to Identify Biomarkers for Chemopreventive Drug Activity
|
1R03CA137777-01
|
$76,750
|
$76,750
|
MANCINI, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel Gene Networks in Breast Development and Cancer
|
5P01CA030195-26
|
$2,398,875
|
$47,978
|
Oesterreich, Steffi
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer
|
2P50CA058183-14
|
$2,300,000
|
$276,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
$4,691
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-02
|
$1,515,000
|
$60,600
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Antiestrogen Regulation of Bladder Cancer
|
1R03CA119271-01A2
|
$76,750
|
$76,750
|
SMITH, CAROLYN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targets of Vitamin D Receptor Action in Prostate
|
5R01CA107691-05
|
$292,538
|
$292,538
|
Weigel, Nancy
|
BAYLOR COLLEGE OF MEDICINE
|
|
Botanical-derived drug discovery for cancer therapy
|
1R43CA114876-01A2
|
$130,207
|
$130,207
|
Norris, Andrew
|
BCN BIOSCIENCES, LLC
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$36,260
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Synergy between phytochemicals for prostate cancer prevention
|
5R03CA130133-02
|
$85,000
|
$85,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
In utero availability of the essential nutrient, choline, and mammary cancer risk
|
5R21CA120488-02
|
$162,500
|
$81,250
|
BLUSZTAJN, JAN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Characterizing disease and treatment response in colon cancer chemoprevention
|
1K05CA131504-01
|
$163,042
|
$163,042
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Women's Health Study: Continued Follow-up
|
5R01CA047988-18
|
$1,680,173
|
$1,680,173
|
BURING, JULIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
|
5P50CA105009-05
|
$2,176,201
|
$435,240
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Physicians' Health Study II: Prevention Trial of Vitamins
|
5R01CA097193-07
|
$1,563,010
|
$1,563,010
|
GAZIANO, J
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Mouse Models for Human Cancer
|
5U01CA084301-10
|
$935,254
|
$140,288
|
KUCHERLAPATI, RAJU
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Hormones, hormone-related genes, and colorectal cancer
|
5K07CA112529-04
|
$106,649
|
$106,649
|
Lin, Jennifer
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Nutritional and Genetic Markers of Breast Cancer
|
5R01CA104871-04
|
$282,620
|
$282,620
|
ZHANG, SHUMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
New Approaches to Prevent or Treat Breast Cancer Metastases
|
1R21CA129470-01A1
|
$227,745
|
$113,873
|
GRAVEKAMP, CLAUDIA
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
PHASE I AND II CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS
|
N01CN035160-008
|
$750,000
|
$750,000
|
MEYSKENS, FRANK
|
CALIFORNIA UNIVERSITY IRVINE:1110253
|
|
Nutritional Intervention Trials in Linxian China-Continued Follow-Up
|
N01RC477001-002
|
$58,939
|
$58,939
|
DONG, ZHI-WEI
|
Cancer Inst (Hos) Chinese Acad. Med Scie
|
|
Early Detection of Esophageal Cancer
|
N01RC477002-002
|
$200,000
|
$50,000
|
DONG, ZHI-WEI
|
Cancer Inst (Hosp) Chinese Acad. Med Sch
|
|
Carle Cancer Center Community Clinical Oncology Program
|
2U10CA035195-25
|
$855,703
|
$68,456
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
Identification of the molecular mechanism of a potent chemopreventive agent, CDDO
|
1F31CA134211-01
|
$39,398
|
$39,398
|
Gatbonton, Tonibelle
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Clinical Oncology Research Career Development Program (CORP)
|
2K12CA076917-11A1
|
$720,391
|
$72,039
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-18S3
|
$234,254
|
$18,740
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S1
|
$72,416
|
$5,793
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S2
|
|
$0
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-19
|
$5,104,000
|
$408,320
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanisms of Prostate Cancer Chemoprevention by Apigenin
|
5R01CA108512-05
|
$228,488
|
$228,488
|
GUPTA, SANJAY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Molecular Mechanisms of GSTP1 Reactivation by Green Tea Polyphenols
|
5R01CA115491-02
|
$264,195
|
$264,195
|
GUPTA, SANJAY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Determinants of Chemoprevention by SERMs
|
5R03CA130066-02
|
$77,250
|
$77,250
|
MONTANO, MONICA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Retinoic acid, CRABP, and cancer
|
5R01CA107013-04
|
$363,658
|
$363,658
|
NOY, NOA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
DISCOVERY AND EVALUATION OF NOVEL TRITERPENOID CHEMOPREVENTIVES IN A NEW COLON CA
|
1R03CA132168-01A1
|
$78,396
|
$78,396
|
Tochtrop, Gregory
|
CASE WESTERN RESERVE UNIVERSITY
|
|
REGULATORY SUPPORT FOR CANCER PREVENTION AGENT DEVELOPMENT
|
N02CN433011-004
|
$1,210,200
|
$1,210,200
|
SIGMAN, CAROLINE
|
CCS ASSOCIATES INC
|
|
TECHNICAL INFORMATION RESEARCH RESOURCES FOR CANCER PREVENTIVE AGENT DEVELOPMENT
|
N02CN433015-005
|
$2,102,488
|
$2,102,488
|
SIGMAN, CAROLINE
|
CCS ASSOCIATES INC:1109683
|
|
Cedar Rapids Oncology Project
|
2U10CA052352-19
|
$575,627
|
$46,050
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
Multi-Center Study of Pancreatic Cancer Etiology
|
5R01CA102765-05
|
$1,070,318
|
$214,064
|
MANDELSON, MARGARET
|
CENTER FOR HEALTH STUDIES
|
|
Assessing the Impact of Colorectal Cancer Screening
|
5U01CA097427-07
|
$215,923
|
$75,573
|
RUTTER, CAROLYN
|
CENTER FOR HEALTH STUDIES
|
|
Action of Novel Retinyl Ethers in Breast Cancer Control
|
5R01CA108498-05
|
$281,848
|
$281,848
|
SANI, BRAHMA
|
CHEMOPREVENTIA, LLC
|
|
Chemoprevention of Basal Cell Carcinomas with Tazarotene
|
5R01CA109584-05
|
$1,005,301
|
$1,005,301
|
EPSTEIN, ERVIN
|
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
|
|
S1P Lyase in colon cancer
|
5R01CA129438-02
|
$318,197
|
$79,549
|
SABA, JULIE
|
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
|
|
METALLOPROTEINASE INHIBITORS IN TUMOR PROGRESSION
|
5R01CA042919-20
|
$253,961
|
$83,807
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-22
|
$1,042,698
|
$83,416
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Regulation of androgen metabolism by the nuclear receptor CAR
|
5R03CA127415-02
|
$84,500
|
$42,250
|
HUANG, WENDONG
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
PHASE IIB RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF AN NSAID FOR THE MODULATION OF
|
N01CN025140-004
|
|
$0
|
HUSSEIN, MOHAMAD
|
Cleveland Clinic Foundation
|
Total relevant funding to Chemoprevention for this search: $168,074,275
|